Ardais Pursues New Business Model; Duke Cancer Alliance Is Inaugural Deal | GenomeWeb

Ardais is taking itself one step closer to becoming a pharmacogenomics player — and in the process is changing the way it does business.

This week, the closely held tissue-banking company said it has begun helping researchers at Duke University Medical Center collect and store tissue samples from women with breast cancer.

The deal, which uses Ardais’ newly launched Biospecimen Management System, or BMS, will also equip Duke scientists and oncologists with a repository of molecular data collected from these samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.